Early Diagnostics Quadrant Biosciences focuses on epigenetic diagnostics for neurological disorders including autism, Parkinson’s, and mTBI, presenting a potential opportunity to expand collaborations with hospitals, clinics, and payers seeking innovative early-detection tools.

ASD Platform Launch of Clarifi ASD in 2023 positions the company as a first mover in epigenetic testing for autism, creating sales potential with pediatricians, neurologists, and ASD-focused treatment centers seeking breakthrough diagnostic solutions.

COVID Pivot Past rapid pivot to COVID-19 testing and FDA EUA for Clarifi COVID-19 Test Kit demonstrates capabilities in rapid assay development and regulatory agility, which can be leveraged for new infectious disease or biomarker-based screening partnerships.

Funding & Collaboration NIH grant of 2.3M and ongoing awards, plus leadership hires in clinical and diagnostic testing, indicate strong credibility and potential collaboration avenues with academic medical centers, research consortia, and contract development partners.

Growth Signals Revenue scale (10–25M) with a relatively lean employee base and notable industry awards suggests a scalable sales story to large health systems and specialty labs seeking innovative diagnostics, complemented by strategic partnerships and distribution opportunities.